In the same week that Genentech confirmed it's cutting 3% of its staff, the Roche subsidiary has terminated a cell therapy partnership with Adaptimmune Therapeutics worth up to $3 billion. The collaboration, inked in 2021, was a licensing deal focused on the development of two types of allogeneic T-cell therapies. At the time, Genentech paid out $150 million in cash. Since then, Adaptimmune has earned $35 million in milestone payments. Source: Fierce Biotech 12/4/2024